Amneal Pharmaceuticals Inc expected to post earnings of 9 cents a share - Earnings Preview

Amneal Pharmaceuticals

01/05/2024 13:40

* Amneal Pharmaceuticals Inc  AMRX.OQ   AMRX.O  is expected
to show a rise in quarterly revenue when it reports  results on
May 3 for the period ending March 31 2024
    * The Bridgewater New Jersey-based  company is expected to
report
a 11.0% increase in revenue to $619.033 million from $557.54
million a year ago, according to the mean estimate from 4
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Amneal Pharmaceuticals
Inc is
for earnings of 9 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Amneal
Pharmaceuticals Inc is $7.50​, above​ its last closing price
of $6.05. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  0.09        0.09       0.14      Beat    55.2
 Sep. 30 2023  0.16        0.13       0.19      Beat    49.8
 Jun. 30 2023  0.11        0.11       0.19      Beat    79.2​
 Mar. 31 2023  0.10        0.10       0.12      Beat    25
 ​​Dec.        0.21        0.21       0.23      Beat    9.9
 31 2022                                                
 Sep. 30 2022  0.18        0.18       0.14      Missed  -20.8​
 Jun. 30 2022  0.19        0.19       0.19      Met     -2.2
 Mar. 31 2022  0.13        0.13       0.12      Missed  -7.2
 This summary was machine generated May 1 at 12:40 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)